Gastrointestinal Cancer News

Calling the research “beyond impressive” and “absolutely remarkable,” HCPs took to Twitter to heap praise on study results presented at the ASCO Annual Meeting describing treatment with dostarlimab in a subset of rectal cancer patients.

In its 2022 Cancer Disparities Progress Report, American Association for Cancer Research discussed advances made in closing substantial gaps in care while underscoring the need for further progress.

SAN DIEGO — In a Healio video exclusive, study authors Howard P. Monsour, MD, and Carrie Milliard, discuss how genetic risk assessment and testing may help inform patient care and improve health outcomes.

CHICAGO — Acetaminophen suppressed antitumor immunity in a cohort of patients with cancer, according to study results presented during ASCO Annual Meeting.

The potential for ctDNA-guided management to reduce adjuvant chemotherapy by half without compromising recurrence-free survival sparked interest on social media after a presentation at the ASCO Annual Meeting.

CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed.

CHICAGO — The addition of panitumumab vs. bevacizumab to standard doublet chemotherapy significantly extended survival among patients with RAS wild-type and left-sided metastatic colorectal cancer, according to study results.

CHICAGO — During the ASCO Annual Meeting, Healio honored our inaugural Healio Disruptive Innovators in hematology/oncology.

CHICAGO — Circulating tumor DNA analysis safely reduced adjuvant chemotherapy use without compromising recurrence-free survival among patients with stage II colon cancer, according to results of the randomized phase 2 DYNAMIC trial.

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to randomized phase 3 study results presented at ASCO Annual Meeting.